Enovis (NYSE:ENOV) Stock Rating Lowered by Zacks Research

Enovis (NYSE:ENOV) was downgraded by Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued on Monday,Zacks.com reports.

A number of other research firms have also weighed in on ENOV. Wells Fargo & Company lowered their target price on Enovis from $42.00 to $40.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Needham & Company LLC upped their target price on Enovis from $49.00 to $52.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Weiss Ratings restated a “sell (e+)” rating on shares of Enovis in a report on Friday, April 10th. William Blair initiated coverage on Enovis in a report on Friday, April 17th. They set an “outperform” rating for the company. Finally, Wall Street Zen upgraded Enovis from a “hold” rating to a “buy” rating in a report on Sunday, May 10th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $44.50.

Enovis Stock Up 0.8%

Shares of NYSE ENOV opened at $21.87 on Monday. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.05 and a current ratio of 2.04. The firm has a market capitalization of $1.26 billion, a price-to-earnings ratio of -1.10 and a beta of 1.38. The stock has a 50 day moving average price of $24.02 and a 200 day moving average price of $24.98. Enovis has a 52-week low of $20.82 and a 52-week high of $36.82.

Enovis (NYSE:ENOV) last posted its earnings results on Thursday, May 7th. The company reported $0.89 earnings per share for the quarter, topping analysts’ consensus estimates of $0.82 by $0.07. The company had revenue of $589.15 million during the quarter, compared to analyst estimates of $572.02 million. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.Enovis’s revenue was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.81 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Sell-side analysts expect that Enovis will post 3.65 earnings per share for the current year.

Institutional Trading of Enovis

Hedge funds and other institutional investors have recently made changes to their positions in the business. Arax Advisory Partners purchased a new stake in shares of Enovis during the 4th quarter valued at $29,000. EverSource Wealth Advisors LLC lifted its holdings in shares of Enovis by 125.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after purchasing an additional 707 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of Enovis by 353.5% during the 4th quarter. GAMMA Investing LLC now owns 1,855 shares of the company’s stock valued at $49,000 after purchasing an additional 1,446 shares during the last quarter. Atlantic Union Bankshares Corp purchased a new stake in shares of Enovis during the 3rd quarter valued at $64,000. Finally, Danske Bank A S purchased a new stake in shares of Enovis during the 3rd quarter valued at $64,000. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.